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A BS TR AC T
BACKGROUND
Congenital abnormalities of the kidney and the urinary tract are the most common 
cause of pediatric kidney failure. These disorders are highly heterogeneous, and the 
etiologic factors are poorly understood.
METHODS
We performed genomewide linkage analysis and whole-exome sequencing in a 
family with an autosomal dominant form of congenital abnormalities of the kidney 
or urinary tract (seven affected family members). We also performed a sequence 
analysis in 311 unrelated patients, as well as histologic and functional studies.
RESULTS
Linkage analysis identified five regions of the genome that were shared among all 
affected family members. Exome sequencing identified a single, rare, deleterious vari-
ant within these linkage intervals, a heterozygous splice-site mutation in the dual 
serine–threonine and tyrosine protein kinase gene (DSTYK). This variant, which 
resulted in aberrant splicing of messenger RNA, was present in all affected family 
members. Additional, independent DSTYK mutations, including nonsense and splice-
site mutations, were detected in 7 of 311 unrelated patients. DSTYK is highly expressed 
in the maturing epithelia of all major organs, localizing to cell membranes. Knock-
down in zebrafish resulted in developmental defects in multiple organs, which 
suggested loss of fibroblast growth factor (FGF) signaling. Consistent with this 
finding is the observation that DSTYK colocalizes with FGF receptors in the ure-
teric bud and metanephric mesenchyme. DSTYK knockdown in human embryonic 
kidney cells inhibited FGF-stimulated phosphorylation of extracellular-signal-regu-
lated kinase (ERK), the principal signal downstream of receptor tyrosine kinases.
CONCLUSIONS
We detected independent DSTYK mutations in 2.3% of patients with congenital ab-
normalities of the kidney or urinary tract, a finding that suggests that DSTYK is a 
major determinant of human urinary tract development, downstream of FGF sig-
naling. (Funded by the National Institutes of Health and others.)
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Congenital malformations of the kidney and urinary tract contribute to 23% of birth defects1,2 and account for 40 
to 50% of pediatric cases and 7% of adult cases 
of end-stage renal disease (ESRD) worldwide.3,4 
These disorders are genetically heterogeneous 
and encompass a wide range of anatomical de-
fects, such as renal agenesis, renal hypodyspla-
sia, ureteropelvic junction obstruction, or vesico-
ureteral reflux.5 Mutations in genes that cause 
syndromic disorders, such as HNF1B and PAX2 
mutations, are detected in only 5 to 10% of cas-
es.6,7 Familial forms of nonsyndromic disease 
have been reported, further supporting genetic 
determination8,9; however, owing to locus het-
erogeneity and small pedigree size, the genetic 
cause of most familial or sporadic cases remains 
unknown.
We studied a family with an autosomal 
dominant form of congenital abnormalities of 
the kidney and urinary tract (Fig. 1A; and Table S1 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org).8 Seven 
family members were classified as affected on 
the basis of the presence of a solitary kidney, 
renal hypodysplasia, ureteropelvic junction ob-
struction, or vesicoureteral reflux, as document-
ed by means of imaging studies. The mean age 
at diagnosis was 12 years (range, 1 to 37). Three 
family members (members 7, 8, and 13), all with 
ureteropelvic junction obstruction, had ESRD at 
a young age (at 8, 10, and 23 years of age, re-
spectively), without other known causes of renal 
failure, such as diabetes mellitus or uncontrolled 
hypertension. Epilepsy developed in these three 
persons during their third decade of life. The 
other affected family members did not have evi-
dence of renal dysfunction at the last follow-up 
visit. Seven family members were classified as 
unaffected on the basis of normal ultrasono-
graphic studies of the abdomen and normal re-
nal function, and six were classified as having 
an unknown phenotype, owing to unavailable or 
indeterminate ultrasonographic studies.
A series of 311 patients with congenital ab-
normalities of the kidney and urinary tract was 
studied to identify independent mutations. Ge-
netic and clinical data for 7 of these patients (5 of 
whom had congenital obstructive uropathy) are 
shown in Table 1 and Figure 1.
ME THODS
GENOTYPING AND SEQUENCING
After genomewide genotyping, we conducted a 
genomewide analysis of linkage, under an auto-
somal dominant mode of inheritance, with as-
signment of phenotype only to affected persons 
(affected-only analysis). Rare copy-number vari-
ants were excluded with the use of HumanHap 
650Y Genotyping BeadChips (Illumina). Whole-
exome sequencing and analysis were performed 
as previously described10,11 in two members of 
the family (members 13 and 19).
We performed Sanger sequencing of DSTYK to 
validate exome data and detect independent mu-
tations in 311 unrelated patients with congenital 
abnormalities of the kidney and urinary tract and 
in 384 healthy European controls matched to 
patients with DSTYK mutations according to self-
reported ethnic group; 96 of these controls were 
also matched according to recruitment site. Cod-
ing exons and flanking introns of HNF1B, PAX2, 
and EYA1 were sequenced in the 7 patients car-
rying DSTYK mutations. We determined allele 
frequencies with the use of public databases, 
scores from Polymorphism Phenotyping, version 
2 (PolyPhen-2), and alignment in 22 mammalian 
species.
Written informed consent was obtained from 
all the participants. The study was approved by 
the institutional review board at each participat-
ing site. All the authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the study to the protocol.
LYMPHOCYTE IMMORTALIZATION  
AND DNA ANALYSIS
We generated lymphoblastoid cell lines from 17 
family members. Total RNA was isolated, comple-
mentary DNA (cDNA) was generated, and Sanger 
sequencing was performed on the cDNA with the 
use of primers spanning the exon 2 and 3 bound-
aries.
IMMUNOHISTOCHEMICAL AND 
IMMUNOFLUORESCENCE TESTING
DSTYK expression was examined in adult and 
embryonic mouse organs (embryonic day 15.5 to 
18.5) and in a kidney and ureter from a pediatric 
donor (3 months of age; International Institute 
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Figure 1. Identification of DSTYK Mutations in a Family with Congenital Abnormalities of the Kidney and Urinary Tract and the Spectrum 
of Mutations and Phenotypes in Unrelated Patients.
Panel A shows the pedigree of the study family. Squares represent male family members, circles female family members, black symbols 
affected persons, white symbols unaffected persons, gray symbols unknown phenotype, red solid circles DSTYK mutation carriers, and 
red open circles noncarriers of the mutation; slashes indicate deceased family members. Panel B shows the linkage analysis identifying 
five regions (arrows) of the genome reaching the maximal expected LOD score of 1.5. DSTYK is located in the chromosome 1q25–1q41 
locus. Panel C shows a chromatogram of a DSTYK c.654+1 G→A mutation from genomic DNA. Sequence analysis of complementary 
DNA (cDNA) in mutation carriers shows the use of an alternative splice site in exon 2, leading to a 27-bp deletion (Panel D). Panel E 
shows the genomic structure of DSTYK and the location of pathogenic mutations identified in the present study. The exons encoding 
the kinase domain are shown in green. Representative ultrasonographic findings in mutation carriers are shown in Panels F, G, and H, 
with hypoplasia of the left kidney (Panel F, kidneys outlined by dashed lines) detected at birth in a girl with a p.R29Q mutation, bilateral 
hydronephrosis (Panel G, arrows) caused by ureteropelvic junction obstruction detected at birth in a girl with a c.655−3 C→T mutation, 
and hydronephrosis only of the left kidney (Panel H, arrow) caused by ureteropelvic junction obstruction in a 5-year old boy with a p.R29Q 
mutation. The intravenous pyelogram in Panel I shows blunting of fornices on the right side (white arrow) and calyceal dilatation on the 
left side (red arrow) in a 2-year-old boy with a p.W8X mutation.
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for the Advancement of Medicine). Immunohisto-
chemical testing was performed with the use of 
anti-DSTYK antibody (also called anti-RIP5 anti-
body; Universal Protein Resource Knowledgebase 
accession number, Q6XUX3; catalogue number, 
sc-162109; Santa Cruz Biotechnology) on paraffin-
embedded tissues with the use of heat-induced 
antigen retrieval. Immunofluorescence testing 
was performed with the use of the following an-
tibodies: anti-RIP5 antibody, antibodies to fibro-
blast growth factor (FGF) receptors 1 and 2 (anti-
FGFR1 and anti-FGFR2 antibodies, respectively), 
anti–aquaporin-2 antibody, and anti–E-cadherin 
antibody (see the Supplementary Appendix).
ZEBRAFISH MORPHOLINO KNOCKDOWN
Morpholino oligomers were designed to block 
the zebrafish dstyk (National Center for Biotech-
nology Information reference sequence number, 
NM_205627.2) exon 9 splice donor and to truncate 
or delete the ATP-binding kinase domain. Morpho-
lino injections were also performed in tumor-
suppressor protein (p53)–mutant homozygotes12 
to control for nonspecific antisense effects.
SMALL INTERFERING RNA KNOCKDOWN  
AND WESTERN BLOTTING
Human embryonic kidney 293T cells were grown 
with the use of standard procedures. The cells were 
transfected with a mixture of DSTYK small inter-
fering RNAs (siRNAs; SMARTpool, Dharmacon); 
for a negative control, we used a pool of siRNA 
that was tested by the manufacturer for not inter-
fering with any transcript. At 72 to 96 hours after 
transfection, the cells were starved in serum-free 
medium and treated with FGF. Blotting was per-
formed as above with the use of goat anti-RIP5 
and rabbit anti-FGFR2 antibodies; mouse anti–
glyceraldehyde-3-phosphate dehydrogenase anti-
body; rabbit anti–phosphorylated extracellular-
signal-regulated kinase (pERK) 1 and 2 and 
anti–extracellular-signal-regulated kinase (ERK) 
1 and 2 antibodies; and horseradish-peroxidase–
labeled sheep antimouse, donkey antigoat, or don-
key antirabbit antibody. Detailed methods are in-
cluded in the Supplementary Appendix.
R ESULT S
HETEROZYGOUS MUTATIONS IN DSTYK 
Genomewide analysis of linkage with the use of 
an affected-only analysis identified five regions 
of the genome that were shared among all seven 
affected members (Fig. 1). These intervals col-
lectively spanned 55.44 Mb (approximately 1.8%) 
of the genome, containing 645 protein-coding 
genes (Table S2 in the Supplementary Appendix). 
Analysis of copy-number variants in all affected 
persons excluded major genomic imbalances 
(data not shown).
Whole-exome sequencing, performed in mem-
bers 13 and 19 of the study family (Fig. 1A) at an 
average depth of coverage of approximately 108 
times per base, identified 14,943 single-nucleotide 
variants (SNVs) across the genome, including 709 
SNVs that were absent in all public databases. 
Among these, 24 protein-altering variants were 
shared by these two patients (missense, nonsense, 
or splice-site variants) (Table S3 in the Supple-
mentary Appendix). Only 2 of these 24 SNVs, 
both on chromosome 1q25–1q41, mapped to the 
linkage intervals.
Follow-up testing by means of Sanger sequenc-
ing detected both SNVs in all affected persons 
and the obligate carrier in the family. One of 
these SNVs (p.A111V in TIMM17A) was common 
among persons of Sardinian ancestry (minor al-
lele frequency, 0.47). The other variant, a ca-
nonical splice-donor SNV at the first base after 
exon 2 (c.654+1 G→A) of DSTYK, encoding a dual 
serine–threonine and tyrosine kinase, was ab-
sent in 48 persons of Sardinian ancestry and 384 
European controls (Fig. 1C). The DSTYK mutation 
was heterozygous in all affected persons, obligate 
carriers, and two apparently unaffected members 
(who were 44 and 20 years old at the last follow-
up visit).
Sequence analysis of DSTYK cDNA from lym-
phoblastoid cell lines in 17 family members 
showed that all mutation carriers had a hetero-
zygous 27-bp deletion resulting from the use of 
an alternative splice donor within the normal 
exon 2, which would result in an in-frame deletion 
of nine amino acids (VTMHHALLQ) in a domain 
that is highly conserved among mammals (Fig. 1, 
and Fig. S1 and S2 in the Supplementary Appendix).
We next searched for independent mutations 
in DSTYK in 311 additional patients with con-
genital abnormalities of the kidney and urinary 
tract. We identified a nonsense mutation (p.W8X) 
in a patient with ureteropelvic junction obstruc-
tion and early-onset ataxia, and a splice-site mu-
tation (c.655−3 C→T) in two siblings affected by 
ureteropelvic junction obstruction. We also iden-
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tified, in 5 other patients, three missense variants 
that occur at completely conserved positions in 
mammals and that were predicted to be damag-
ing according to PolyPhen-2 (p.R29Q, p.D200G, 
and p.S843L). These five damaging variants were 
absent in all public databases and were also not 
detected in the 384 healthy European controls. 
Moreover, none of these patients carried delete-
rious structural variants13 or point mutations in 
HNF1B, PAX2, or EYA1. The phenotypic spectrum 
associated with DSTYK mutations is described in 
Table 1 and shown in Figures 1F through 1I.
Thus, sequence analysis in an independent 
cohort of 311 unrelated patients with congenital 
abnormalities of the kidney and urinary tract 
identified five DSTYK mutations in 7 patients 
(2.3% of this independent cohort) (Table 1). As a 
comparison, the exome variant server (a data-
base hosted by the National Heart, Lung, and 
Blood Institute that contains exome data for 
6503 people) does not contain any DSTYK non-
sense mutations or variants affecting the three 
canonical nucleotides flanking splice junctions. 
Only 0.3% of white persons (14 of 4300) in this 
database have rare damaging DSTYK missense 
variants affecting completely conserved positions 
in mammals (11 variants with a minor allele fre-
quency of <0.001), indicating a significant excess 
burden of rare damaging variants among persons 
with congenital abnormalities of the kidney and 
urinary tract (7 of 311 affected persons [2.3%]; 
odds ratio, 7.1; P = 0.0003 by Fisher’s exact test).
UBIQUITOUS EXPRESSION OF DSTYK  
ON CELL MEMBRANES
DSTYK has a striking membrane-associated dis-
tribution in mesenchymal-derived cells of all 
major organs (Fig. S3 in the Supplementary Ap-
pendix). In the developing mouse kidney, it is 
expressed at low levels in the nephrogenic zone 
but is more highly expressed in maturing tubular 
epithelia, with the most prominent expression in 
the medulla and the papilla (Fig. S3G, S3H, and 
S3I in the Supplementary Appendix). In postnatal 
mouse and human pediatric kidneys, DSTYK is 
detected in the basolateral and apical membranes 
of all tubular epithelia (Fig. 2A through 2D, and 
Fig. S4 in the Supplementary Appendix). It has 
both a basolateral and a cytoplasmic distribution 
in the thin ascending limb of the loop of Henle 
and the distal convoluted tubule, but expression 
is restricted to apical and basolateral membranes 
in the collecting duct, including the principal 
and intercalated cells (Fig. 2A through 2D, and 
Fig. S5 in the Supplementary Appendix). DSTYK 
was also detected in all layers of transitional ure-
teric epithelium and in the ureteric smooth-mus-
cle cells (Fig. 2D).
MORPHOLINO KNOCKDOWN IN ZEBRAFISH
To investigate the role of DSTYK in embryonic 
development, we performed knockdown of the 
orthologue in zebrafish. With maximal knock-
down, embryos showed growth retardation, as 
evidenced by small fins, abnormal morphogene-
sis of the tail, and loss of heartbeat (Fig. S6 in the 
Supplementary Appendix); we also observed clo-
acal malformations that correspond to lower 
genitourinary defects in mammals and defects in 
jaw development, as well as specific loss of the 
median fin fold. Pericardial effusion was evident 
in 5-day-old morphant larvae, which was attrib-
utable to both heart and kidney failure. These 
data suggest an essential role of DSTYK in the 
development of major organs. The observed de-
velopmental defects resemble phenotypes produced 
by global loss of FGF signaling in zebrafish.14-16
COLOCALIZATION OF DSTYK AND FGF RECEPTORS 
and effect on erk phosphorylation
In the developing mouse nephron (embryonic 
day 15.5), DSTYK colocalizes with cells that are 
E-cadherin–positive and those that are E-cad-
herin–negative, confirming its expression in both 
the metanephric mesenchyme and the ureteric 
bud (Fig. 2G and 2H). DSTYK localization to the 
cell membrane in the metanephric mesenchyme 
and ureteric bud highly parallels the known ex-
pression pattern of FGF receptors. Joint immu-
nostaining confirmed that DSTYK colocalizes 
with both FGFR1 and FGFR2 in the ureteric bud 
and comma-shaped bodies (Fig. 2G and 2H, and 
Fig. S7 in the Supplementary Appendix). Colocal-
ization with FGFR2 was also evident in distal tu-
bular cells in the adult renal medulla and papilla 
(Fig. S8 in the Supplementary Appendix). Punc-
tate DSTYK staining was seen at apical cell–cell 
junctions lining the ureteric-bud epithelia (Fig. 
S9 and S10 in the Supplementary Appendix).
On activation, FGF receptors trigger cytoplas-
mic protein kinases, resulting in ERK phosphory-
lation, which is the main effector of FGF-induced 
transcriptional activity.17,18 Because DSTYK en-
codes a kinase and colocalizes with FGFR1 and 
FGFR2, we hypothesized that DSTYK acts as a 
positive regulator of FGF-mediated signaling in 
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Figure 2. DSTYK Expression in the Human and Mouse Urinary Tract and Small Interfering RNA (siRNA) Knockdown Studies.
Panels A through D show DSTYK expression in the kidney and ureter of a 3-month-old child. Panel A shows the glomerulus (Glom) 
and macula densa (MD). Panel B shows the renal cortex with ascending limbs of loop of Henle (AL) and collecting ducts (CD). Panel C 
shows the CD in the renal medulla, with punctate staining at the basolateral side (arrows). Panel D shows the smooth-muscle layer 
(Sm) and urothelium (Ur) of the ureter. Panels E through H show DSTYK colocalizing with fibroblast growth factor (FGF) receptors. 
Immunofluorescence analysis in a developing murine kidney (embryonic day 15.5) shows DSTYK (red) colocalization with FGF re-
ceptor 1 (FGFR1; green) (Panel E), FGF receptor 2 (FGFR2; green) (Panels F, G, and H) and E-cadherin (Panel H; blue). In Panel I, 
DSTYK knockdown is shown to inhibit FGF-mediated phosphorylation of extracellular-signal-regulated kinase 1 and 2 (ERK 1 and 2); 
siRNA knockdown of DSTYK in 293T cells starved in serum-free medium shows a significant reduction in the DSTYK level at 96 hours 
after knockdown. FGF stimulation significantly augments phosphorylated ERK (pERK 1 and 2), but DSTYK knockdown abrogates FGF-
mediated ERK phosphorylation. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. MM denotes 
metanephric mesenchyme, and UB ureteric bud.
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the kidney. To test this hypothesis, we per-
formed siRNA knockdown of DSTYK in the hu-
man embryonic kidney-cell line 293T, which re-
sulted in a reduction of up to 80% in transcript 
levels and a pronounced reduction of DSTYK 
protein levels within the first 96 hours after 
transfection (Fig. 2I, and Fig. S11 in the Supple-
mentary Appendix). FGF stimulation augmented 
the levels of phosphorylated ERK (pERK) as ex-
pected, but siRNA silencing of DSTYK signifi-
cantly prevented ERK phosphorylation (Fig. 2I). 
This effect was not mediated by a direct physical 
interaction of DSTYK with FGFR2 (Fig. S12 in 
the Supplementary Appendix). Combined with 
colocalization of DSTYK with FGFR1 and FGFR2, 
these data implicate DSTYK downstream of FGF 
signaling.
DISCUSSION
The development of the kidney and the urinary 
tract is orchestrated by a series of inductive sig-
nals between the metanephric mesenchyme and 
the ureteric bud, and any disruption of this recipro-
cal signaling results in developmental defects.19-22 
The diversity of signaling pathways in nephro-
genesis explains the significant locus hetero-
geneity of congenital abnormalities of the kidney 
and urinary tract.20 For example, in a recent study 
involving 522 patients with kidney malformations, 
we identified 72 distinct copy-number disorders in 
87 patients, suggesting that virtually every patient 
may have a unique genetic diagnosis.13
In the current study, we identified independent 
mutations in DSTYK in 2.3% of patients with 
congenital abnormalities of the kidney and uri-
nary tract. The identification of a heterozygous 
nonsense mutation suggests haploinsufficiency 
as a potential genetic mechanism, underscoring 
a critical role of DSTYK gene dosage in the devel-
opment of the human urinary tract. Mutations 
were detected in patients with defects in the ure-
ter and renal parenchyma, an observation that is 
consistent with DSTYK expression in the ureteric 
bud and metanephric mesenchyme. These find-
ings show the effectiveness of exome sequencing 
for the elucidation of heterogeneous developmen-
tal traits with modest-sized pedigrees.
In humans, a total of 22 FGF ligands signal 
through four FGF receptors, conferring both com-
plexity and redundancy to this pathway.17,23 Dif-
ferent combinations of FGF ligands are expressed 
in the ureteric bud, metanephric mesenchyme, 
and renal stroma,17 and a recessive FGF20 muta-
tion was recently reported in a family with renal 
agenesis.21 FGFR1 and FGFR2 are responsible 
for most of the FGF signaling during nephro-
genesis.17,22,24 Engagement of the FGF receptor 
results in autophosphorylation and activation of 
the intracellular mitogen-activated protein kinase 
cascade, ultimately resulting in the production of 
pERK, the main effector of the FGF transcriptional 
program.17,23
Our data indicate that DSTYK is a positive 
regulator of ERK phosphorylation downstream 
of FGF-receptor activation. A previous study has 
suggested a role of DSTYK in the induction of 
apoptosis, a pathway also regulated by FGF sig-
naling.25 Additional studies will therefore be 
required to delineate the precise role of DSTYK 
in this signal-transduction cascade. Identification 
of other components of this pathway may eluci-
date additional forms of congenital abnormali-
ties of the kidney and urinary tract in humans.
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